Unilife Corp (Nasdaq:UNIS) Scores Yet Another Quarterly Loss

[[tagnumber 0]][[tagnumber 1]]The shares of Unilife Corp (Nasdaq:UNIS) fell 3.05% yesterday as they closed trade at $2.38 on a volume of slightly less than one million. The move occurred following Chairman Alan Shortall‘s presentation at the Jefferies 2015 Global Healthcare Conference. Thus, the developer of injectable drug delivery systems failed to get out of the downtrend it had started in early–April and currently stands much closer to its 52–week low value of $2.00 per share.[[tagnumber 2]] [[tagnumber 0]]UNIS closed the quarter ended Mar. 31, 2015 with cash reserves in excess of $39 million. At the same time, revenue more than doubled on an annual basis as the company raked in a total of $2.9 million this time. So, revenue surged considerably and so did the quarterly loss. At over $23.6 million, this is UNIS‘s biggest loss for the last four quarters on record. Moreover, it is 60% higher than the loss incurred in the corresponding quarter of 2014. The cumulative loss for the nine–month period ended Mar. 31, 2015 now exceeds $64 million as opposed to $42 million the year prior.[[tagnumber 2]] [[tagnumber 0]]The loss mentioned above has forced management raise external capital through a mix of debt and equity financing schemes. During the nine months leading up to the end of March 2015, UNIS issued long–term debt for $20 million and raised another $57 million via stock offering, thus making for a total capital injection of more than $77 million. Considering that UNIS has so far only issued half of its total authorized stock, one could safely assume that there seems to be plenty of room for potential dilutive measures that might be taken by management in the forthcoming months.[[tagnumber 2]] [[tagnumber 0]][[tagnumber 8]]As stated in Unilife‘s most recent 10–Q, the company offers a “broad portfolio of proprietary product platforms“ relating to its injectable drug delivery systems. What is more, CEO Alan Shortall and his fellow directors have made it clear that the company‘s main focuse will be to pursue long–term strategic agreements with pharmaceutical businesses to ensure sustainable business growth. If carried out properly, this could give UNIS stock the push it needs to break out. There‘s a catch, though. It is unlikely to happen overnight.[[tagnumber 2]]